City Therapeutics, Inc., a biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, presented ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...

Nearly 1.3 billion adults around the world have clinically high blood pressure, many of whom may be unaware that they are living with this condition. Nearly 1.3 billion adults around the world have ...

Please provide your email address to receive an email when new articles are posted on . Three phase 2 trials demonstrated the efficacy and safety of RNA interference therapy for the treatment of mixed ...

Please provide your email address to receive an email when new articles are posted on . The receptor for advanced glycation end-products (RAGE) regulates pathways that contribute to inflammation.

ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase ...

PHILADELPHIA, PA—Zilebesiran (Alnylam), an investigational therapeutic agent that interferes with messenger RNA to stop the production of angiotensinogen (AGT), lowers systolic blood pressure levels ...

In a recent study published in The New England Journal of Medicine, researchers evaluate the efficacy of plazosiran treatment on fasting triglyceride levels in adult patients with mixed hyperlipidemia ...

The liver APOC3-targeted RNA interference agent plozasiran proved its triglyceride-lowering effects in people with mixed hyperlipidemia in the phase IIb MUIR trial. In such individuals, known to be at ...